KUALA LUMPUR, Malaysia, April 29, 2015 /PRNewswire/ -- Australian-listed Holista CollTech Ltd ("Holista"; ASX: HCT) said today that it has secured Asia Pacific distribution rights for Geltox Skin Science, a breakthrough solution that produces a "botox-like" effect to reduce or remove skin wrinkles using plant extracts -- without the need for injections.
Geltox Skin Science has developed tiny water- and fat-soluble liposomes that can penetrate the skin. The liposomes coat and transport anti-ageing active ingredients that increase efficiency and lower toxicity of the encapsulated ingredients which, after penetration, are absorbed and diffused better in the body -- minus the pain and hassle of syringes and needles requiring qualified professionals.
Developed by Spain-based Palma Biotech, patent-pending Geltox Skin Science uses a combination of plant-based peptides to cause mild paralysis in specific muscles reducing facial expression lines including frowns. Similar to Botox®, the effects are immediate upon application and, over time, remove the lines altogether -- except injection is no longer required.
Palma Biotech, a specialist in liposomes and liposomal encapsulation technologies, works with different active compounds that can be paired with its Liposome expertise. Holista, which distributes supplements, natural ingredients and wellness products, has developed and patented its own sheep collagen. Along with the distribution rights, Holista intends to collaborate with Geltox Skin Science to develop sheep collagen liposomes for cosmetic applications.
"Geltox Skin Science is a breakthrough technology which has many applications for cosmetics and even medical use. By eradicating the need for injections, it offers a pain-free alternative which will gain wide acceptance across the region, including younger men and women. Beyond our existing range of sheep collagen, we now have a new avenue of growth with a unique technology," said Dr. Rajen Manicka, CEO of Holista which is headquartered in Kuala Lumpur, Malaysia.
Mr. Frode Thengs-Vik, the CEO and Co-Founder of Palma Biotech, said, "The product is registered, approved and used in Europe. It is manufactured as per standards of the European Union."
"We are pleased to have found an Australian partner that can take our unique innovation to the Asian Pacific region which is now one of the most dynamic markets in the world," said Mr. Olav Hellebo, Chairman of the Board and Co-Founder of Palma Biotech.
Business Enquiries:
Enquiries@holistaco.com
Media Enquiries:
WeR1 Consultants
Ms. Sheryl Sim; sheryl@wer1.net
+65-6737-4844
